USANA Health Sciences Form 4 Shows Routine RSU Vesting by Director
Rhea-AI Filing Summary
USANA Health Sciences (USNA) Form 4 – Director Ding Xia reported routine equity transactions dated 24 Jul 2025.
- Exercise of RSUs (Code M): 1,058 restricted stock units converted 1:1 into common shares, increasing direct holdings.
- Tax‐withholding sale (Code F): 265 shares were surrendered at $32.09 to satisfy withholding obligations.
- Post-transaction ownership: 5,337 common shares held directly and 3,172 unvested RSUs remain outstanding. RSUs vest 25 % on four quarterly dates between 24 Jul 2025 and 23 Apr 2026.
No purchase or sale of shares for investment purposes occurred; the net change (+793 shares) stems from normal equity compensation. No other directors or officers are listed, and there is no indication of material information affecting USNA’s operations or outlook.
Positive
- None.
Negative
- None.
Insights
TL;DR: Standard RSU vesting; neutral cash flow impact.
The filing details a straightforward RSU conversion for Director Ding Xia. Code M shows equity issuance; Code F reflects share forfeiture to cover taxes, a non-cash event for USANA. The director’s net stake rose to 5,337 shares, a de-minimis amount (<0.03 % of shares outstanding), providing no directional signal on insider sentiment. The remaining 3,172 RSUs will amortize over the next three quarters, resulting in slight dilution (<0.02 %). Overall impact on shareholders is negligible.
TL;DR: Routine Section 16 filing; governance posture unaffected.
This Form 4 complies with Section 16(a) reporting and presents no red flags. The attorney-in-fact signature and timely filing indicate strong governance practices. Because transactions were automatic (Rule 16b-3), they are generally excluded from short-swing profit considerations. Investors should view the disclosure as procedural rather than indicative of strategic intent or performance expectations.